Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VISHAL GUPTA

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1255449179
CMS profile
11387
Location
ORANGE CITY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$11,495.23

71 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VISHAL GUPTA

NPI 1255449179 · CMS profile ID 11387

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ORANGE CITY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1255449179?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VISHAL GUPTA, NPI 1255449179, CMS profile ID 11387. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255449179?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). VISHAL GUPTA, NPI 1255449179, CMS profile ID 11387. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255449179?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
VISHAL GUPTA, NPI 1255449179, CMS profile ID 11387, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1255449179?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

71 matching records · $11,495.23 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 71 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–71 of 71.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $23.2104/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175179527 CMS
Gilead Sciences, Inc. $24.0504/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234483884 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.6804/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232018591 CMS
Lilly USA, LLC $22.3803/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186955755 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.8503/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223880523 CMS
Medtronic, Inc. $2,500.0003/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1214687845 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.2203/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232018589 CMS
Janssen Biotech, Inc. $24.3303/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175180082 CMS
Medtronic, Inc. $10.6103/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219990807 CMS
Gilead Sciences, Inc. $23.6803/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234487660 CMS
AnX Robotica Corp $79.3902/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254255548 CMS
Janssen Biotech, Inc. $7.3402/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175178158 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.0302/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223866254 CMS
Janssen Biotech, Inc. $20.3902/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175178941 CMS
Janssen Biotech, Inc. $24.8602/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175178415 CMS
SpringWorks Therapeutics, Inc. $17.4301/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232162985 CMS
E.R. Squibb & Sons, L.L.C. $18.7701/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184579551 CMS
ABBVIE INC. $28.7301/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201981333 CMS
Lilly USA, LLC $19.6501/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186965110 CMS
Aimmune Therapeutics, Inc. $24.5301/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249701787 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.7301/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223817560 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $857.04 49
PY2020 $570.40 34
PY2021 $916.14 56
PY2022 $762.74 46
PY2023 $5,944.01 51
PY2024 $4,151.02 85
PY2025 $11,495.23 71

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $291,326.42 72
PY2024 Principal investigator $285,496.00 78
PY2023 Principal investigator $290,422.00 23
PY2020 Principal investigator $1,000.00 1
PY2019 Principal investigator $3,364.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

72 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 12/22/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223290036
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 12/22/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223290038
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 12/22/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223290040
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,750.00 12/22/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223290042
Principal investigator 1 Genentech, Inc. $276.00 11/26/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211665284
Principal investigator 1 Bausch Health US, LLC $1,370.00 11/06/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224847002
Principal investigator 1 Genentech, Inc. $683.17 11/05/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211665280
Principal investigator 1 Bausch Health US, LLC $1,370.00 10/06/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224847009
Principal investigator 1 Bausch Health US, LLC $2,175.00 10/06/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224847014
Principal investigator 1 Bausch Health US, LLC $1,370.00 10/06/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224847026
Principal investigator 1 Genentech, Inc. $207.00 09/24/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211664954
Principal investigator 1 Bausch Health US, LLC $2,175.00 09/03/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846745
Principal investigator 1 Bausch Health US, LLC $1,709.00 09/03/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846794
Principal investigator 1 Bausch Health US, LLC $2,175.00 09/03/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846870
Principal investigator 1 Bausch Health US, LLC $1,273.00 09/03/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846873
Principal investigator 1 Genentech, Inc. $5,400.00 09/03/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211665107
Principal investigator 1 Bausch Health US, LLC $2,000.00 08/22/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846777
Principal investigator 1 Bausch Health US, LLC $750.00 08/22/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846844
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,250.00 08/21/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184229873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,118.00 08/21/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184229875
Principal investigator 1 Genentech, Inc. $36,022.00 07/25/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211665044
Principal investigator 1 Bausch Health US, LLC $414.00 07/23/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846796
Principal investigator 1 Bausch Health US, LLC $1,709.00 07/23/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846799
Principal investigator 1 Bausch Health US, LLC $1,709.00 07/23/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846821
Principal investigator 1 Genentech, Inc. $2,553.00 07/18/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211664985
Principal investigator 1 Genentech, Inc. $5,214.00 07/16/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211665092
Principal investigator 1 Bausch Health US, LLC $414.00 07/07/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846756
Principal investigator 1 Bausch Health US, LLC $1,370.00 07/07/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846760
Principal investigator 1 Bausch Health US, LLC $414.00 07/07/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846813
Principal investigator 1 Bausch Health US, LLC $1,597.00 07/07/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846839
Principal investigator 1 Genentech, Inc. $40,660.00 06/06/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211664874
Principal investigator 1 Genentech, Inc. $1,449.00 06/04/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211664819
Principal investigator 1 Bausch Health US, LLC $2,175.00 06/02/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846922
Principal investigator 1 Bausch Health US, LLC $2,175.00 06/02/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846926
Principal investigator 1 Bausch Health US, LLC $1,370.00 06/02/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846930
Principal investigator 1 Bausch Health US, LLC $1,597.00 06/02/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846964
Principal investigator 1 Bausch Health US, LLC $1,597.00 06/02/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846984
Principal investigator 1 Bausch Health US, LLC $414.00 06/02/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846987
Principal investigator 1 Genentech, Inc. $690.00 05/28/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211664814
Principal investigator 1 Genentech, Inc. $4,340.00 05/23/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211664834
Principal investigator 1 Genentech, Inc. $92,200.00 05/07/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211664864
Principal investigator 1 Bausch Health US, LLC $1,652.00 05/02/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846881
Principal investigator 1 Bausch Health US, LLC $1,709.00 05/02/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846885
Principal investigator 1 Bausch Health US, LLC $1,709.00 05/02/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846918
Principal investigator 1 Bausch Health US, LLC $1,273.00 05/02/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846941
Principal investigator 1 Bausch Health US, LLC $414.00 05/02/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846944
Principal investigator 1 Bausch Health US, LLC $414.00 05/02/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846952
Principal investigator 1 Bausch Health US, LLC $1,273.00 05/02/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846975
Principal investigator 1 Bausch Health US, LLC $414.00 04/02/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846889
Principal investigator 1 Bausch Health US, LLC $1,652.00 04/02/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846960
Principal investigator 1 Bausch Health US, LLC $1,652.00 04/02/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846971
Principal investigator 1 Bausch Health US, LLC $414.00 04/02/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846991
Principal investigator 1 Bausch Health US, LLC $414.00 04/02/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846997
Principal investigator 1 Genentech, Inc. $2,766.00 03/12/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211664546
Principal investigator 1 Bausch Health US, LLC $1,597.00 03/07/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846640
Principal investigator 1 Bausch Health US, LLC $1,597.00 03/07/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846667
Principal investigator 1 Bausch Health US, LLC $414.00 03/07/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846687
Principal investigator 1 Bausch Health US, LLC $414.00 03/07/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846691
Principal investigator 1 Genentech, Inc. $2,927.25 02/12/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211664506
Principal investigator 1 Bausch Health US, LLC $1,597.00 02/07/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846632
Principal investigator 1 Bausch Health US, LLC $1,273.00 02/07/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846636
Principal investigator 1 Bausch Health US, LLC $414.00 02/07/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846645
Principal investigator 1 Bausch Health US, LLC $1,597.00 02/07/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846655
Principal investigator 1 Bausch Health US, LLC $414.00 02/07/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846663
Principal investigator 1 Bausch Health US, LLC $414.00 02/07/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846706
Principal investigator 1 Bausch Health US, LLC $1,597.00 02/07/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846714
Principal investigator 1 Bausch Health US, LLC $1,652.00 01/08/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846651
Principal investigator 1 Bausch Health US, LLC $414.00 01/08/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846659
Principal investigator 1 Bausch Health US, LLC $414.00 01/08/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846670
Principal investigator 1 Bausch Health US, LLC $1,764.00 01/08/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846679
Principal investigator 1 Bausch Health US, LLC $1,273.00 01/08/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846698
Principal investigator 1 Bausch Health US, LLC $414.00 01/08/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846733